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Abstract
Multi-morbidity, the co-occurrence of multiple physical or psychological illnesses, is prevalent 
particularly among older adults. The number of Americans with multiple chronic diseases is 
projected to increase from 57 million in 2000 to 81 million in 2020. However, behavioral medicine 
and health psychology, while focusing on the co-occurrence of psychological/psychiatric disorders 
with primary medical morbidities, have historically tended to ignore the co-occurrence of primary 
medical comorbidities, such as diabetes and cancer, and their biopsychosocial implications. This 
approach may hinder our ecologically valid understanding of the etiology, prevention, and 
treatment of individual patients with multi-morbidity. In this selective review, we propose a 
heuristic biobehavioral framework for the etiology of multi-morbidity. More acknowledgment and 
systematic research on multiple, co-existing disorders in behavioral medicine is consistent with the 
biopsychosocial model’s emphasis on treating the “whole person,” which means not considering 
any single illness, its symptoms, risk factors, or mechanisms, in isolation. As systems analytics, 
big data, machine learning, and mixed model trajectory analyses, among others, come on-line and 
become more widely available, we may be able to tackle multi-morbidity more holistically, 
efficiently and satisfactorily.
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“No longer can each chronic illness be considered in isolation,” (1).
“Multi-morbidity,” which refers to an individual experiencing the co-occurrence of two or 
more chronic diseases (including for example, asthma, arthritis, diabetes, heart disease, 
hypertension, cancer, and human immunodeficiency virus infection), is common, especially 
in older adults, that is, persons over 60 years of age (1–5). Approximately 57 million 
Americans had multiple chronic diseases in 2000 and the number is projected to be 81 
million in 2020 (2). Such persons also exhibit rapid declines in health status and greater 
likelihood of disability (3,5,6,7,8). Co-occurrence of illnesses is also costly; 66% of total 
health care spending currently is for care of those Americans with multi-morbidity (9).
Presence of one chronic disease is often associated with a greater than expected, subsequent 
occurrence of other disorders (10), [e.g., diabetes with the risk of colorectal cancer (11); 
melanoma with death from amyotrophic lateral sclerosis (12); depression with diabetes or 
coronary heart disease (13, 14)]. As these examples show, the co-occurrence of multiple 
diseases crosses organ and system divides (10). Such clinical and epidemiological 
observations suggest a synergistic or activated process might underlie the emergence of 
multiple chronic conditions (15) that may have profound implications for research, treatment 
and health policy (16–18). Medical research, however has tended to adopt a “one-disease-at-
a-time” approach; whereby the incidence of single diseases has been the focus until recently. 
This approach is being reconsidered as the proportion of the population of persons at risk or 
living with multiple concurrent illnesses is increasing.
Psychosomatic and behavioral medicine have had a more complicated relationship with this 
issue. On the one hand, the co-occurrence of psychological/psychiatric disorders (e.g., 
depression and anxiety) and psychosocial factors (e.g., early adversity, personality factors, 
socioeconomic status) with primary medical morbidities has been the focus of 
psychosomatic and behavioral medicine since the fields began. However, the relationship 
between the biobehavioral mechanisms and factors contributing to the co-occurrence or 
successive occurrence of multiple, primary medical conditions, for instance in patients with 
both diabetes and cancer or heart disease and arthritis, has not been a point of emphasis. 
This paper proposes a biobehavioral framework and future directions for examining the co-
occurrence of multiple primary medical morbidities.
What Should We Call It?
“Multi-morbidity” is often confused with the more common term, “co-morbidity” but 
maintaining a distinction between them is preferable. Co-morbidity refers to the presence of 
other diseases in addition to an index disease (15, 19). For example, specialty care clinicians 
and researchers may be interested in a patient’s heart disease as a primary condition and 
consider any coexistent diseases as subsidiary. There are situations, especially in primary 
care, where someone has multiple disease conditions and no particular illness is the 
exclusive focus. The term, multi-morbidity, seems more appropriate for such scenarios.1
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It is important to distinguish between multiple diseases whose co-occurrences would be 
expected from base-rate probabilities (i.e., simple multi-morbidity) versus co-occurrences 
exhibited at greater than expected probability (i.e., associative multi-morbidity) (26). As an 
example of the first kind, Prados-Torres (27) observes hypertension often co-occurs with 
other conditions because it is a highly prevalent disorder. In contrast, nonrandom 
associations of health disorders represent cases of associative multi-morbidity. This second 
category may help identify the patients at greatest illness risk, and encourage more frequent 
screening and design of special prevention programs, including targeting screening. 
Subsumed under associative multi-morbidity is causal multi-morbidity for which shared risk 
factors, genetic, physiological and psychosocial disease pathways may be operating (26). 
Instances of causal multi-morbidity, such as the cluster comprised of single vessel vascular 
disease, hypertension, diabetes and chronic renal insufficiency, should be excellent 
candidates for multiple levels of analysis in behavioral medicine research and receive 
emphasis in the present paper.2
Most of the currently available evidence on multi-morbidity relies on cross-sectional 
methods. This type of evidence provides a snapshot of the prevalence of pairings and triads 
of different diseases (4,30) but the developmental trajectories of these diseases are unclear 
(10, 18). The mapping of trajectories of emergence and succession of multiple morbidities 
has the potential to assess how close they are to each other with respect to pathogenic 
mechanisms (27). Valuable information already has been mined from existing cohorts, such 
as the combined Center for Medicare and Medicaid Services claims data and Surveillance, 
Epidemiology and End Results Program (SEER) resources (30), although those sources lack 
data about untreated and/or undetected conditions, and are restricted to older adults.
Current challenges in defining and identifying multi-morbidity, mapping multiple disease 
etiology and trajectories may seem daunting, especially in view of the challenges associated 
with studying one-condition at a time for behavioral researchers. However, as systems 
analytics, big data, machine learning, and mixed model trajectory analyses, among others, 
come on-line and become more widely available, we may be able to tackle multi-morbidity 
more holistically, efficiently and satisfactorily.
1Another term, multiple chronic conditions (MCC), is used in recent initiatives by the Department of Health and Human Services (20, 
21), Agency for Healthcare Research and Quality (22) and the Patient-Centered Outcomes Research Institute (23) and sometimes is 
treated synonymously with multimorbidity. The U.S. Department of Health and Human Services designation, however, refers to both 
illnesses and “conditions” (e.g., “risk for falls” in the latter category) lasting a year or more and requiring ongoing medical attention 
and/or limit activities of daily living (24). We prefer multi-morbidity because of its focus on illness and because MCC implies a 
“snapshot” of the patient although in many cases one illness emerges prior to the others (10, 15). The phrase, “complex” or 
“complicated” patients has also been applied to multiple disease scenarios, but the ways that patients are complex or complicated is 
left ambiguous. Observers also have expressed concerns that these terms may lay the blame on the patient (25). The phrase 
“complicated patient,” as frequently used, also includes persons with psychosocial difficulties and few financial resources so it does 
not seem appropriate for our present purposes.
2In describing multi-morbidities, we are focusing on the co-occurrence of different diagnosable physical and psychiatric/psychological 
disorders. Some dispositional risk factors for disease, such as social isolation, perceived stress and hostility, also tend to co-occur and 
may be causally related (28, 29), but they do not qualify as diagnosable medical conditions. Extended discussion of their relationship 
and implications for multi-morbidities is beyond the scope of this paper, but they are briefly considered in a subsequent section, 
“Future Directions.”
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A Biobehavioral Framework for Multi-Morbidity Etiology
Decades of progress in behavioral medicine have identified basic mechanisms whereby 
behavioral and biological interactions contribute to the initiation, progression, treatment and 
recovery from single diseases (32,33). The same processes also likely have applicability to 
those with multi-morbidity. Page’s “Mosaic Theory” of hypertension (34)—positing the 
combined role of several factors—may be an appropriate first-step. Eventually in the area of 
hypertension, empirical investigations of the roles of genetics, environment, adaptive, neural, 
mechanical, and hormonal perturbations led to identification of common molecular and 
cellular events. So too, a mosaic framework may serve as a heuristic for an etiological model 
of multi-morbidity that eventually may lead to research that identifies a small core-set of 
critical processes.
Our mosaic framework first considers factors involved in the etiology of single disease 
conditions and includes: (a) genetics; (b) Autonomic Nervous System arousal (e.g., heart 
rate variability, sympathetic nervous system, parasympathetic nervous system); (c) 
neurohormones (e.g., Hypothalamic-Pituitary-Adrenal Axis and catecholamines); (d) 
immune system-related measures (e.g., inflammation, micro-organisms, etc.); (e) oxidative 
stress; (f) chronic and environmental stress; (g) negative and positive affective dispositions; 
(h) socioeconomic status; (i) behavioral risk factors. (See Figure 1; the two-way arrows 
acknowledge the cross-effects or “traffic,” among these factors.) This list is not exhaustive 
and we recognize that the latent constructs overlap.
The framework for the multi-morbidity scenario depicted in Figure 2 (left panel) includes 
the same factors, such as shared genes, ANS arousal, neurohormones, immune-system 
related factors, negative and positive affective dispositions, shared behavioral risk factors, 
etc., as in Figure 1. In one causal multi-morbidity scenario, two or more diseases emerge 
more or less at the same time because of some shared subset of the factors listed in the left 
panel. Hypothyroidism and obesity would be one such example (35). Other causal multi-
morbidity scenarios involve the development of one condition followed later by another 
condition (or conditions) as a function of the downstream biological effects of the initial 
disease, acute or chronic stress induced by diagnosis and treatment of the initial disease 
and/or the side-effects of medical treatment (Figure 2, Right panel). The model also 
recognizes that development of a second or third, disease condition may in turn produce 
recursive, cascading loops, all of which may amplify the biological and psychosocial insults 
to the system.
In the multi-morbidity scenario, the simultaneous or staggered emergence of two or more 
diseases should be more likely if they are related to the same organ systems or are caused by 
the same set of factors (referred to as causal multi-morbidity above). For example, our 
earlier examples of hypertension, single vessel vascular disease, diabetes and chronic renal 
insufficiency are typically classified as related comorbid conditions, whereas hypertension, 
asthma and gastritis are often considered unrelated (36, 37). A more systematic approach for 
categorizing diseases as related is based on shared genetic susceptibility or other shared 
pathways or mechanisms (see 38 for description of the “diseasome”—the combined set of 
all known disorder/disease genetic associations). An example of genetic commonality is the 
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co-occurrence of Alzheimer’s Disease and myocardial infarction where an apolipoprotein E 
allele is implicated (39). A complementary approach identifies common metabolic-based 
defects among disease phenotypes (40). The co-occurrence of diabetes and colorectal and 
bladder cancers may represent, in part, shared metabolic pathways (41) (see below).
Examples of staggered emergence of diseases
The thirty percent increased risk of colorectal cancer conferred by diabetes, suggested a 
downstream effect of the first emerging condition on the second (11). While both diseases 
share similar risk factors, physical inactivity and obesity (42), diabetes and cancer appear to 
be positively associated even with these risks controlled (11). The downstream effect of 
diabetes may stem from constant exposure to hyperinsulimia, which is associated with 
production of insulin-like growth factor that can cause cell-proliferation and inhibit 
apoptosis (42,43), thereby increasing tumor growth. This is an illustration of how two or 
more successive diseases can result from metabolic defects—the cell’s inability to 
breakdown a metabolic substrate—that can have a cascading effect that leads to the coupling 
(or co-occurrence) of diverse diseases (40). In a metabolic disease network in which two 
diseases are linked, mutated enzymes associated with the disorders catalyze adjacent 
metabolic reactions.
Medication-Related Multi-morbidity
Worthy of special mention (see Figure 2, right panel) is the role of medical treatment and 
medications in contributing to multi-morbidity. Approval of new drugs by the Food and 
Drug Administration (FDA) requires evidence of efficacy through phase 3 clinical trials of 
one index condition (our emphasis). This means that possible drug-to-drug, drug-to-disease, 
and disease-to-disease interactions are frequently unknown and potentially life-threatening 
(44). Besides improving safety, more proactive measurements of any drug toxicity may 
provide insights about multi-morbidity. As an illustration, the recognition that 
anthracyclines, which are widely and effectively used for the treatment of breast cancer, 
increase the long-term risk of heart failure has motivated the development of oncology-
cardiology partnerships and revision of clinical guidelines (45, 46). Another example is the 
use of pegylated interferon – alpha (IFN-α) to treat chronic hepatitis patients, which has the 
side-effect of inducing depression in 23 to 45% of patients (47) probably because IFN 
reduces serotonin levels (48), and/or activates other proinflammatory cytokines and the 
hypothalamic-pituitary-adrenal (HPA) axis, which can induce depression (49).
Future Directions for Research in Multi-Morbidity and Behavioral Medicine
Recognition of the prevalence of multi-morbidity and the proposed framework suggests 
several research directions for behavioral medicine. Below we present some illustrative 
examples from five general categories: (a) epidemiology; (b) autonomic imbalance; (c) 
animal models; (d) symptom perception, treatment-seeking and medical diagnosis; and (e) 
behavioral interventions and evidence-based clinical guidelines.
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Clinical and Behavioral Epidemiology
Medicine, public health and behavioral medicine need large, representative longitudinal 
cohorts that recruit persons earlier in life (e.g., middle-age) to obtain a comprehensive 
picture of when multiple illnesses initially emerge and whether there are common multi-
morbidity trajectories. For behavioral medicine researchers, critical questions will address 
the role of illness- and non-illness related stressors and cumulative psychosocial burdens or 
emerging behavioral disruptions associated with highly prevalent or common multi-
morbidity phenotypes (50). Therefore, assessment of psychosocial variables, such as stress, 
social support, negative affective dispositions, etc., should be an important component of any 
large-scale epidemiological study of emergence and trajectory of multi-morbidity.
Autonomic and HPA Imbalance
Behavioral researchers, positing that exaggerated patterns of physiological reactivity 
experience “wear and tear” on tissues and organs, that eventually lead to bodily dysfunction 
and susceptibility to disease (51, 52), have devoted attention to identifying cardiovascular, 
neuroendocrine and immune reactivity to stressors (53). In studies of mental stress or 
naturalistic stressors with patients with existing illness, however presence of other medical 
disorders tends to be an exclusion criterion. As a result, we lack information about how 
stress-induced laboratory or ambulatory reactivity is influenced by the presence of one or 
more other diseases and whether reactivity has prognostic value for survival or quality of life 
in these common multi-morbid patients. Studies of how reactivity patterns are altered in the 
context of multiple diseases might be enlightening about which stress indices are most 
affected, and whether disease co-occurrence amplifies or decreases the magnitude of 
reactivity. Such results may have prognostic value as well as implicate common disease 
pathways.
Animal models
The use of experimental animal models of disease initiation and progression permits 
manipulation of many of the psychobiological processes described earlier that cannot be 
ethically or feasibly manipulated in humans. Study of multi-morbidity in experimental 
animal models is rare in behavioral medicine, in contrast to extensive research on the effects 
of stress on the initiation and progression of single disorders (54, 55). The development of 
animal models of multiple chronic conditions, incorporating behavioral theory and empirical 
methods, represents a significant opportunity for behavioral medicine researchers. Clearly, 
there are complications, such as the need to identify species for whom multiple disorders can 
be experimentally induced. However, the potential to study genetic, autonomic, and immune 
factors, as well as the variables of interest to the behavioral medicine field, as they affect 
development of multiple diseases using animal models would seem to have great potential.
Symptom Perception, Treatment Seeking and Medical Diagnosis
In the multi-morbidity scenario, patients may have difficulty deciding whether a new 
symptom is just another manifestation of their known condition, or if another disease has 
emerged that may need medical attention. Part of the difficulty is that common symptoms 
frequently cross multiple diseases, and symptoms cluster as well (56). Laypeople have 
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commonsense or mental models of illness, acquired through socialization, modeling and folk 
transmission, that guide how they label somatic changes and infer that they are experiencing 
symptoms (57–59). As an example, some studies indicate that most people have a mental 
model for heart attack including such features as severe chest pain, sweating, and labored 
breathing (60). Perceived somatic changes that match the person's mental model are labeled 
as symptoms and may initiate self-care or medical treatment-seeking. Lacking a match, 
however the person may discount the changes as benign or minor or take a “wait-and-see” 
approach. People also use heuristic rules, such as “if symptoms develop gradually they are 
probably due to aging and not to illness,” (61) —that prompt them to discount the somatic 
changes and not seek care. In short, multi-morbidities that present with a complex pattern of 
physical changes may create uncertainty for the patient about what they are experiencing 
and whether there is cause for additional medical or psychological diagnosis and consequent 
treatment. Much more is known about the diagnosis of single diseases than multiple 
conditions. Often, each set of symptoms is referred to a different medical specialist, which 
can produce uncoordinated care and even iatrogenesis if consideration of the entire set of 
diseases, and their complex interplay is not managed differently than is being done in 
current practice.
Although research on commonsense models and illness heuristics has acknowledged that 
circumstances (such as aging or stressful events; 62) can complicate symptom perception 
and interpretation, the implications of the multi-morbidity scenario for self-care, treatment-
seeking, diagnosis and treatment-planning have not been systematically explored. This is 
another future research direction for behavioral medicine.
Behavioral Intervention and Clinical Guidelines
Outside of the research context, evidence-based clinical guidelines tend to focus on single 
diseases (63), which means patients with multiple chronic diseases, and the health 
practitioners who treat them, have to cope with problems of coordination of care (64, 65) 
and conflicting guidelines (66). For example, a recommendation of physical activity, which 
would be helpful for chronic obstructive pulmonary disease, may be contraindicated for a 
patient who also has osteoarthritis of the hip. The general absence of clear clinical guidelines 
that do not conflict for treating the patient with multiple morbidities represents a significant 
gap. Some progress, however, is being made in developing and testing alternative co-
morbidity-adapted protocols for patients with the most prevalent combinations of concurrent 
diseases (67).
There is a possibility for synergistic effects of applying a behavioral intervention to multi-
morbidity. If we shift to the related area of prevention, sometimes it may be better to have 
multiple targets. For example, Spring, et al. (68) noted that suboptimal diet and sedentary 
behavior tend to cluster as risk behaviors and tested whether intervening simultaneously on 
both may have synergistic benefits. In a randomized clinical trial involving remote coaching 
supported by mobile decision support technology and financial incentives, the condition in 
which both diet and activity were behavioral targets fared the best. Perhaps a behavioral 
intervention that targets two disorders simultaneously allows the patient to build on the 
initial successes with one condition. Also, because behavioral interventions often target 
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maladaptive cognitive appraisals and affective responses, which can apply to multiple illness 
conditions, there may be cumulative improvement.
Another hypothesis, based on the “diseasome” and human metabolic networks described 
earlier (38, 40), is that multiple diseases, characterized as “close,” that is have a family 
resemblance, based on genes, common mechanisms, interrelated metabolic pathways, or 
shared risk behaviors, may be more responsive to the same kinds of behavioral interventions 
than are “distant” co-occurring disorders. This hypothesis is worthy of future research 
attention.
Challenges to Studying Multi-Morbidity
Although we think it is the right time and behavioral medicine has the appropriate tools to 
systematically address the topic of multi-morbidities, we also appreciate that logical, 
empirical and logistical challenges exist. Two are described below.
Heterogeneity in Measuring Multi-morbidity
The identification of patients with multiple chronic illnesses is typically based on disease 
counts taken from medical records or on clinician or patient checklists (69). Different 
criteria are used to create counts; sometimes they are based on diseases, health problems or 
larger categories of “related diseases,” which may vary depending on the clinician’s mental 
models. The most used common illness checklists also are based on different categorical 
dimensions. For example, the Cumulative Illness Index (70) collects ratings of severity of 
impact on 14 distinct organ systems, whereas the Charlson (71) inquires about 14 to 22 
distinct diseases. This means there may be considerable variability in the classification of 
patients with multi-morbidity. We think that advances in network medicine (38,40), based on 
shared genes and metabolic pathways, offer the potential to improve classification of multi-
morbidity.
Diagnosis of multi-morbidity also creates challenges. Having been diagnosed and clinically 
managed for one condition, the probability that others will be identified may increase 
because of increased medical scrutiny, or ascertainment bias (18, 72). However, there may 
also be an opposing (negative ascertainment) bias: in some cases, diagnostic procedures for 
other conditions (e.g., an asymptomatic cancer) may not be administered. For example, 
Alzheimer’s patients may be reported to have a lower cancer malignancy rate because they 
are less likely to be referred for cancer screening (73).
Patient numbers
Some questions about multi-morbidity will require researchers to add new comparison 
groups to their experimental or observational research designs. For example, to test whether 
cognitive behavioral therapy is less effective, or synergistic, in hypertension management for 
patients who also have another chronic condition, it will be necessary to have experimental 
treatment, usual-care or attention-placebo arms for patients with multiple conditions and for 
patients with only hypertension. Besides additional labor and expense, there will be a need 
for more participants to attain sufficient statistical power to detect effects. It is well-known 
that recruitment numbers for clinical trials are far below what is desirable and several 
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strategies are currently being tested to improve recruitment rates. Encouraging more 
research on patients with co-occurring illnesses probably will be seen as a significant 
challenge for trialists and other researchers, who currently are having problems recruiting 
the requisite numbers just for patients with a single condition.
There is no simple solution, but it should be emphasized that the proportion of patients with 
multiple disorders is expected to grow as the population ages. Also, it is ironic that one 
reason researchers encounter difficulties in RCT recruitment is because patients with co-
occurring conditions are often excluded from trials. Although recruitment may be 
challenging, the upside is clinical inferences will be based on more representative samples, 
and interesting new insights will be attained about the usefulness of behavioral medicine 
interventions and mechanistic approaches to those with multi-morbidity.
Conclusions
With the aging of the population (74), the prevalence of persons with multiple health 
problems will only increase. Furthermore, medical advances in cancer and heart disease, as 
examples, have extended survival so more people will live longer with multiple chronic 
diseases. Neither mainstream medicine nor behavioral medicine, based mainly on a “one-
disease-at-a-time” approach, has fully recognized or addressed the increasing problem of 
multi-morbidity of primary medical conditions. Understanding the genesis of multiple 
diseases, their biological and psychosocial consequences and how best to prevent and treat 
them underscores the need for multiple levels of analysis and transdisciplinary science. 
Behavioral medicine and health psychology, which incorporate both features because they 
subscribe to the biopsychosocial model, have much to offer for understanding and improving 
the well-being of patients with multi-morbidity.
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Biopsychosocial Factors of Single Disease Etiology
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Reciprocal Effects of Biopsychosocial Factors of Single Disease and Multi-Morbidity 
Etiology
(left panel) includes the same factors, such as shared genes, autonomic arousal, 
neurohormones, immune system-related activity, negative and positive affective dispositions, 
shared behavioral risk factors, etc., as in Figure 1. In one scenario, two or more diseases 
emerge more or less simultaneously because of a shared subset of the factors, listed in the 
left panel. The right panel depicts the staggered emergence of other conditions as a function 
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of downstream biological effects of the initial disease, acute/chronic stress induced by 
diagnosis and treatment of the initial disease and/or the side-effects of medical treatment.
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